stockrow
Monday 2 November 2026
Export TWST’s income statement to Excel — free account
Twist Bioscience Corporation
TWST Healthcare Biotechnology
Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.
- Revenue
- +23.2%
- EPS
- −264.7%
- Free cash flow
- −7.23%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
129.86
22.92
−15.00%
Follow TWST
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
14.87 | 7.16 | 4.95 | 4.47 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
5,757.87 | (166.98) | (78.08) | (142.46) | |
P/B ratio |
14.40 | 6.44 | 4.25 | 3.56 | |
Price to Tangible BV |
18.30 | 8.15 | 5.37 | 4.46 | |
EV/Sales |
14.52 | 6.78 | 4.48 | 3.90 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(118.14) | (49.96) | (34.42) | (30.80) | |
EV/FCF |
(65.57) | (29.22) | (20.25) | (19.40) | |
Quick Ratio |
1.93 | 1.97 | 3.08 | 3.17 | |
Current Ratio |
2.67 | 2.70 | 3.78 | 3.64 | |
Net Debt/EBITDA |
5.15 | 3.97 | 6.85 | 9.09 | |
Debt/Assets |
2.23% | 2.22% | 2.35% | 2.34% | |
Debt/Equity |
0.03 | 0.03 | 0.03 | 0.03 | |
Asset Turnover |
0.66 | 0.64 | 0.63 | 0.60 | |
Operating CF/Net income |
(0.03) | 0.40 | 0.81 | 0.44 | |
Capex/Depreciation |
(1.44) | (1.25) | (1.61) | (2.49) | |
Research and Development Expense of Revenue |
15.23% | 17.79% | 16.52% | 17.18% | |
Selling, General and Administrative Expense of Revenue |
68.18% | 68.72% | 67.25% | 64.40% | |
Intangible Assets out of Total Assets |
0.14 | 0.14 | 0.15 | 0.15 | |
Share Based Compensation of Revenue |
15.35% | 17.10% | 12.80% | 16.24% | |
Graham Net Nets |
0.01 | 0.03 | 0.06 | 0.10 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.16%) | (2.78%) | (4.00%) | (4.62%) | |
Free Cash Flow Yield |
(1.49%) | (3.24%) | (4.48%) | (4.49%) | |
Revenue per Share |
1.90 | 1.79 | 1.70 | 1.66 | |
Operating CF per Share |
0.02 | (0.28) | (0.41) | (0.20) | |
Capex per Share |
(0.16) | (0.13) | (0.16) | (0.25) | |
Free Cash Flow per Share |
(0.14) | (0.41) | (0.57) | (0.45) | |
Cash per Share |
2.67 | 2.78 | 3.24 | 3.89 | |
Shareholders Equity per Share |
7.14 | 7.38 | 7.47 | 7.91 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.14 | 7.38 | 7.47 | 7.91 | |
Free Cash Flow |
(8.65) | (25.55) | (34.79) | (26.74) | |
Working Capital |
201.04 | 203.46 | 223.44 | 241.56 | |
Capital Expenditures |
(9.76) | (7.99) | (9.97) | (14.93) | |
Net Current Asset Value |
94.60 | 102.32 | 121.89 | 164.06 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.08 | 0.07 | 0.10 | 0.15 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
57.45 | 57.05 | 44.69 | 45.96 | |
Average Payables |
14.51 | 11.37 | 10.00 | 6.36 | |
Average Inventory |
30.55 | 27.19 | 28.22 | 26.19 | |
Average Assets |
658.02 | 635.91 | 623.33 | 628.09 | |
Average Common Equity |
461.97 | 447.60 | 456.02 | 472.82 |
Columns are period end dates